Literature DB >> 12719860

[Antipruritic effects of pimecrolimus and tacrolimus].

S Ständer1, T A Luger.   

Abstract

The development of topical calcineurin inhibitors resulted in a significant improvement in the treatment of inflammatory skin diseases such as atopic dermatitis. In addition, an excellent amelioration of pruritus could be observed. Other itchy dermatoses such as chronic irritative hand dermatitis, rosacea, graft-versus-host-disease, renal pruritus, lichen sclerosus, prurigo simplex, prurigo nodularis, scrotal eczema, and inverse psoriasis also have been treated successfully with pimecrolimus and tacrolimus. The antipruritic effect currently is believed to be related to the inhibition of inflammatory cytokines. Furthermore, recent investigations indicate a release of neuropeptides from sensory nerve fibers and degranulation of mast cells mediated by pimecrolimus and tacrolimus. Similar effects have been observed during capsaicin treatment. These findings may provide a possible explanation for initially observed calcineurin inhibitors related side-effects such as burning and pruritus. Moreover, the antipruritic potency may be related to a direct effect on nerve fibers leading to suppression of itch mediated by unknown mechanisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12719860     DOI: 10.1007/s00105-003-0521-6

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  27 in total

1.  Treatment of prurigo nodularis with topical capsaicin.

Authors:  S Ständer; T Luger; D Metze
Journal:  J Am Acad Dermatol       Date:  2001-03       Impact factor: 11.527

2.  Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients.

Authors:  C J Choi; P Nghiem
Journal:  Arch Dermatol       Date:  2001-09

3.  Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report.

Authors:  D Goldman
Journal:  J Am Acad Dermatol       Date:  2001-06       Impact factor: 11.527

4.  Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children.

Authors:  S Kang; A W Lucky; D Pariser; I Lawrence; J M Hanifin
Journal:  J Am Acad Dermatol       Date:  2001-01       Impact factor: 11.527

5.  Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis.

Authors:  Sakari Reitamo; Edwin J M Van Leent; Vincent Ho; John Harper; Thomas Ruzicka; Kirsti Kalimo; Frédéric Cambazard; Malcolm Rustin; Alain Taïeb; David Gratton; Daniel Sauder; Graham Sharpe; Catherine Smith; Michael Jünger; Yves de Prost
Journal:  J Allergy Clin Immunol       Date:  2002-03       Impact factor: 10.793

6.  Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug.

Authors:  Alexander Kapp; Kim Papp; Ann Bingham; Regina Fölster-Holst; Jean-Paul Ortonne; Paul C Potter; Wayne Gulliver; Carle Paul; Stephen Molloy; Nathalie Barbier; Mark Thurston; Yves de Prost
Journal:  J Allergy Clin Immunol       Date:  2002-08       Impact factor: 10.793

7.  Successful treatment of anogenital lichen sclerosus with topical tacrolimus.

Authors:  Markus Böhm; Uta Frieling; Thomas A Luger; Gisela Bonsmann
Journal:  Arch Dermatol       Date:  2003-07

Review 8.  Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases.

Authors:  Elke C Bornhövd; Walter H C Burgdorf; Andreas Wollenberg
Journal:  Curr Opin Investig Drugs       Date:  2002-05

9.  Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.

Authors:  Ulrich Wahn; Jan D Bos; Mark Goodfield; Ruggero Caputo; Kim Papp; Ahmed Manjra; Attila Dobozy; Carle Paul; Stephen Molloy; Thomas Hultsch; Michael Graeber; Robert Cherill; Yves de Prost
Journal:  Pediatrics       Date:  2002-07       Impact factor: 7.124

10.  Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study.

Authors:  Michael Meurer; Regina Fölster-Holst; Gottfried Wozel; Gottfried Weidinger; Michael Jünger; Matthias Bräutigam
Journal:  Dermatology       Date:  2002       Impact factor: 5.366

View more
  6 in total

1.  Chronic pruritus: clinics and treatment.

Authors:  Sonja Grundmann; Sonja Ständer
Journal:  Ann Dermatol       Date:  2011-02-28       Impact factor: 1.444

Review 2.  [Lichen sclerosus. New aspects of pathogenesis and treatment].

Authors:  A Marini; S Blecken; T Ruzicka; U R Hengge
Journal:  Hautarzt       Date:  2005-06       Impact factor: 0.751

3.  Pimecrolimus 1% cream for anogenital lichen sclerosus in childhood.

Authors:  Stefanie Boms; Thilo Gambichler; Marcus Freitag; Peter Altmeyer; Alexander Kreuter
Journal:  BMC Dermatol       Date:  2004-10-14

Review 4.  [Rational symptomatic therapy for chronic pruritus].

Authors:  S Ständer
Journal:  Hautarzt       Date:  2006-05       Impact factor: 0.751

Review 5.  [Pruritus in childhood. A diagnostic and therapeutic challenge].

Authors:  E Weisshaar; S Seeliger; T L Diepgen; T A Luger; S Ständer
Journal:  Hautarzt       Date:  2004-09       Impact factor: 0.751

6.  Treatment of pruritic diseases with topical calcineurin inhibitors.

Authors:  Sonja Ständer; Funda Schürmeyer-Horst; Thomas A Luger; Elke Weisshaar
Journal:  Ther Clin Risk Manag       Date:  2006-06       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.